10X Capital Venture Acquisition Corp. III: Nasdaq/NYSE listing notice — 10X Capital Venture Acquisition Corp. III receives NYSE American delisting notice for late 10-K filing

10X Capital Venture Acquisition Corp. III

NYSE American notified 10X III on April 17, 2024, that it failed to timely file its 2023 Annual Report (Form 10-K) due April 16, 2024.
The notice provides a six-month cure period from the original due date to file the delinquent report and regain compliance.
10X III attributes the delay to its independent auditor needing additional time to complete review of year-end financial statements.
The company states it intends to file the Annual Report within the cure period; the notice has no immediate effect on listing.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

10X Capital Venture Acquisition Corp. III received a nyse_american noncompliance notice notice regarding late filing.

Exchange: nyse american
Notice: noncompliance notice
Deficiency: late filing

Exact text from the filing

April 17, 2024, 10X Capital Venture Acquisition Corp. III, a Cayman Islands exempted company (“10X III”), received a written notice (the “Notice”) from New York Stock Exchange Regulation, Inc. indicating that 10X III was not in compliance with the NYSE American LLC’s (“NYSE American”) continued listing standards because 10X III did not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Annual Report”), which was due on April 16, 2024. The Notice provides that 10X III has a period of six months from the due date of the Annual Report (the “Cure Period”)

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-24-035407

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.